Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood filter could save lives in sudden liver failure

NCT ID NCT07178366

Disease control Sponsor: Institute of Liver and Biliary Sciences, India Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a blood purification device called DPMAS for people with acute-on-chronic liver failure (ACLF), a life-threatening condition. About 56 adults will be randomly assigned to standard medical care alone or standard care plus DPMAS. The goal is to see if DPMAS improves liver function and survival without needing a transplant.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Double Plasma Molecular Adsorption System (DPMAS) - a blood purification device
What this could lead to
If it works, DPMAS could offer a way to stabilize liver function and improve survival without needing a transplant for people with acute-on-chronic liver failure.
What could go wrong
This is a small, early-stage trial with only 56 participants. The treatment is not a cure and may not work for everyone. There are also risks from the blood filtering procedure itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 56 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ACLF patients of any etiology with systemic inflammatory response syndrome and AARC grade II or more. Exclusion Criteria: * Patients eligible for corticosteroids for severe alcohol-associated hepatitis related ACLF (other than hydrocortisone according to Surviving Sepsis Campaign Guidelines 2021 which is 50 mg iv q 6 h for management of refractory shock * Hepatocellular carcinoma or any extrahepatic malignancy, * Active fungal sepsis * Disseminated intravascular coagulation * Hemodynamic instability requiring norepinephrine \>0.20ug/kg/min * Patients with coma of non-hepatic origin * Patients with PaO2/FiO2 ratio \<150 * Pregnancy * Comorbidities associated with poor outcomes (severe cardiopulmonary disease defined by a New York Heart Association score \>3, or oxygen/steroid-dependent chronic obstructive pulmonary disease, chronic kidney disease) and patients with post-resection liver failure * Patients with fibrinogen \<110 and/or platelets less than 50,000 * Patients with oliguria with urine output less than 400 ml/day * Lack of informed consent * Patient enrolled in other clinical trials

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute on chronic liver failure (ACLF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Acute-On-Chronic Liver Failure liver failure Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute on chronic liver failure (ACLF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.